Published on 30/11/2025

OTIF vs OTD: Which KPI Matters and When

Understanding key performance indicators (KPIs) is essential for pharmaceutical professionals managing supplier relationships and contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs). Among the various KPIs in use, On-Time In-Full (OTIF) and On-Time Delivery (OTD) are often compared—each with distinct implications for quality assurance, supplier qualification, and overall operational performance. This tutorial guide provides a structured approach for professionals in clinical operations, regulatory affairs, and medical affairs, helping them evaluate when each KPI is relevant and how they align with quality management systems as stipulated by regulations such as ICH Q10 and 21 CFR Part 11.

1. Understanding OTIF and OTD Comprehensively

OTIF and OTD are metrics used to gauge the performance of suppliers and service providers in the pharmaceutical industry. Although these terms are often used interchangeably, they serve different tracking purposes that influence supplier qualification and oversight processes.

1.1 Defining OTD

On-Time Delivery (OTD) represents the percentage of orders delivered by suppliers within the agreed timeframe. It provides a straightforward assessment of a supplier’s punctuality. The formula for OTD is as follows:

• OTD = (Number of Orders Delivered On Time / Total Number of Orders) x 100

Monitoring OTD is crucial for supply chain efficacy, as delays in delivery can critically disrupt production schedules. Compliance programs often require rigorous vendor audits that integrate OTD performance into broader operational assessments.

1.2 Understanding OTIF

On-Time In-Full (OTIF) measures the complete fulfillment of an order, ensuring it is both delivered on time and contains all requested items in the correct quantities. This KPI reflects suppliers’ reliability more comprehensively. The formula for OTIF is as follows:

• OTIF = (Number of Orders Delivered Complete and On Time / Total Number of Orders) x 100

The importance of OTIF cannot be overstated when evaluating CMO/CDMO performance as incomplete orders could lead to additional compliance risks and impact validation deliverables such as tech transfer packages.

2. The Importance of Performance Measurement in CMO/CDMO Oversight

Supplier qualification forms the bedrock of effective pharmaceutical production, ensuring that vendors meet predefined quality benchmarks. Performance measurement through KPIs such as OTIF and OTD enhances decision-making processes regarding supplier relationships. Failure to accurately assess these metrics may inadvertently lead to inadequate oversight.

2.1 Aligning OTIF and OTD with Quality Agreement Clauses

Quality agreements established with CMOs or CDMOs outline the expectations for service delivery and quality standards. These agreements should explicitly define the KPIs (OTD and OTIF) that reflect the supplier’s obligations. Incorporating performance metrics into quality agreement clauses ensures measurable accountability, which aligns with cGMP guidelines.

• Example Clause: “The supplier agrees to maintain an OTIF rate of 95% as part of this quality agreement.”

Incorporating OTIF and OTD into quality agreements not only drives performance but also fosters continuous improvement, enabling ongoing review and risk scoring of supplier capabilities.

2.2 The Role of Vendor Audits

Effective vendor audits serve as a mechanism for assessing compliance with contractual obligations. By evaluating both OTIF and OTD performance during vendor audits, pharmaceutical companies can identify trends, areas for improvement, and potential risks. Detailed audit reports should indicate compliance rates, address discrepancies, and propose corrective actions. This process benefits both parties and aligns with best practices outlined by regulatory bodies such as the FDA and EMA.

3. When to Use OTIF vs. OTD

Deciding whether to prioritize OTIF or OTD metrics depends on the specific goals of your operation and the nature of your products. Below, we detail scenarios that demonstrate when each KPI should take precedence.

3.1 Using OTD as a Standalone Metric

When punctuality alone is paramount—for instance, in situations where the product is less critical or delay doesn’t bear significant financial consequences—OTD stands out as a valuable metric. Example situations could include:

• Routine supplies or non-critical materials.
• Short lead-time orders where a delay would not severely impact production timelines.

In these scenarios, understanding punctuality allows for basic performance tracking without the complexities tied to fulfillment.

3.2 Integrating OTIF for Comprehensive Evaluation

In contrast, OTIF should be used in contexts where product quality and completeness are essential. Examples include:

• Critical active pharmaceutical ingredients (APIs) where precision is mandatory.
• First-time launches or high-value product lines with significant regulatory oversight.

Prioritizing OTIF in these scenarios provides a holistic view of performance, ensuring deliveries meet not only deadlines but also quality standards to mitigate risks associated with validation deliverables and compliance obligations.

4. Implementing an Ongoing Review and Risk Scoring Framework

To ensure continued compliance and performance enhancement, establishing an ongoing review mechanism is essential. This should include regular assessments of both OTIF and OTD metrics through an established risk scoring methodology.

4.1 Setting Up an Ongoing Review Process

An ongoing review should incorporate periodic evaluations, with processes designed to assess both the metrics and input from audits. Steps to create an effective review process include:

• Define Review Frequency: Determine intervals for performance evaluations (e.g., monthly, quarterly).
• Establish a Review Committee: Form a cross-functional team responsible for reviewing performance and KPI adherence.
• Utilize Tools and Software: Implement software solutions that automate data collection and reporting on OTIF and OTD.

4.2 Risk Scoring

Develop a scoring system based on predefined criteria such as compliance with quality agreements, observations from audits, OTD and OTIF performance, and supplier financial stability. This quantitative assessment will help to categorize suppliers based on risk levels, allowing for focused and tailored oversight.

5. Regulatory Expectations and Compliance Considerations

Remaining compliant with regulatory expectations necessitates an understanding of how OTIF and OTD metrics support validation and quality systems as mandated by guidelines like ICH Q10. Pharmaceutical companies must document their performance evaluations, ensuring clarity and transparency regarding supplier oversight processes.

5.1 Current Regulatory Frameworks

Both the FDA and EMA provide guidance on performance measurement and risk management. Compliance with established guidelines within 21 CFR Part 11 reinforces the need for electronic records in managing OTIF and OTD reporting effectively. Ensuring data integrity and security is crucial, especially when these metrics impact validation deliverables. Familiarity with these regulations ensures guided assessments and a lower likelihood of encountering compliance issues.

5.2 Best Practices for Compliance

To comply with regulatory standards effectively, pharmaceutical companies should consider the following best practices:

• Maintain detailed documentation of all performance metrics related to OTIF and OTD.
• Ensure that employee training programs emphasize understanding the significance of these KPIs.
• Regularly update quality agreement clauses to reflect current industry practices associated with OTIF and OTD management.

6. Conclusion: Choosing Between OTIF and OTD

In summary, both OTIF and OTD serve significant roles within the pharmaceutical supply chain, catering to different operational aims. While OTD emphasizes punctuality, OTIF offers a comprehensive view of supplier reliability. Each KPI’s relevance depends on the quality agreement enforceability and the nuances of the production circumstances.

Effective supplier qualification processes and oversight formats relying on these metrics can yield favorable outcomes in compliance, efficiency, and performance, thus enhancing the rampant success of pharmaceutical operations.

In implementing this guide, professionals in quality assurance, quality control, and regulatory affairs can rely on these strategies to elevate their vendor management practices, align with regulatory expectations, and optimize their operational efficiencies.